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Abstract
Background: The study’s aim was to estimate the self-reported prevalence of Human Immunodeficiency Virus (HIV)
and Hepatitis C Virus (HCV), and to describe their associated risk factors in a population of users of illicit drugs
recruited in Catalonia- Spain, during 2012.
Methods: Cross-sectional study. People with illicit drugs use were selected in three different types of healthcare
centres. The questionnaire was a piloted, structured ad hoc instrument. An analysis was made to identify factors
associated to self-reported HCV, HIV and co-infection. Correlates of reported infections were determined using
univariate and multivariate Poisson regression (with robust variance).
Results: Among 512 participants, 39.65 % self-reported positive serostatus for HCV and 14.84 % for HIV, co-infection
was reported by 13.48 %. Among the 224 injecting drug users (IDUs), 187 (83.48 %), 68 (30.36 %) and 66 (29.46 %)
reported being positive for HCV, HIV and co-infection, respectively. A higher proportion of HIV-infected cases was
observed among women, (18.33 % vs. 13.78 % in men). Prevalence of HCV, HIV and co-infection were higher
among participants with early onset of drug consumption, long periods of drug injection or who were
unemployed. A positive serostatus was self-reported by 21(7.34 %) participants who did not report any injection;
among them 16 and eight, reported being positive for HCV and HIV, respectively; three reported co-infection. Only
two people declared exchanging sex for money. For those that reported a negative test, the median time since the
last HIV test was 11.41 months (inter-quartile range (IQR) 4–12) and for the HCV test was 4.5 months (IQR 2–7).
Conclusions: Among drug users in Catalonia, HIV, HCV and co-infection prevalence are still a big issue especially
among IDUs. Women and drug users who have never injected drugs are groups with a significant risk of infection;
this might be related to their high-risk behaviours and to being unaware of their serological status.
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Background
Drug dependence is a complex chronic condition, which
is often related to health problems, such as the risk of ac-
quisition of blood-borne pathogens. People who use
drugs, especially by injection, have been among the first
and largest transmission group for new human immuno-
deficiency virus (HIV) infections [1], and are still a key
transmission group for hepatitis C virus (HCV) [2]. These
infections are among the most costly consequences of
illicit drug use, having a high impact on individuals and
on healthcare systems [3].
Epidemiological studies have described different trans-
mission risk factors for HIV/HCV among drug users.
Injecting drugs is the leading source of infection, and
among non-injecting users it is sexual contact [4].
Among injecting drug users (IDUs), HIV has a global
prevalence of approximately 11.5 % and HCV of 51.0 %
[5], mainly as a result of sharing contaminated syringes
and other injecting equipment [6, 7]. Unprotected sex is
one of the most important risk factors for HIV in drug
users who have never injected drugs [4], with an in-
creased risk of infection by HCV among women and
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men who have sex with men who are co-infected with
HIV or other sexually transmitted diseases [8]. Other
sex-related factors associated with the increased risk of
blood-borne infections (BBI) include a history of a sexu-
ally transmitted disease [9], sex with an IDU partner
[10], exchanging sex for money or drugs [11] and num-
ber of sex partners [12].
Data from surveillance systems and cohort studies
suggest that prevalence of both infections are high
among IDUs. HCV is five times more prevalent than
HIV, and has remained unchanged even in communities
where the rate of HIV infections has fallen [13]. In
Spain, HIV prevalence in IDUs seems to be decreasing,
although it is still high compared with other European
countries [14]. In contrast prevalence of HCV among
IDUs has remained stable or increased slightly in recent
years [3]. In Catalonia, a Spanish Autonomous Commu-
nity, one study showed that during 2006, prevalence of
HIV and HCV among IDUs were 58.1 and 80.1 %, re-
spectively [15], with 50.3 % of co-infection.
In view of the above factors, drug users constitute a vul-
nerable group needing continual surveillance, especially
because they constitute a key group in which to focus pre-
ventive interventions that can reduce transmission of BBI.
The objective of this study was to estimate the prevalence
of self-reported HIV and HCV, and to describe factors as-
sociated with them, in a large sample of consumers of
illicit drugs recruited in Catalonia- Spain, during 2012.
Methods
Study design and population
Cross-sectional study in Catalonia, Spain, where partici-
pants were selected from three different drug healthcare
settings: 1) Substance abuse outpatient treatment centres
(OTC), 2) Harm Reduction facilities (HRF) and 3) Thera-
peutic communities (TC). Sampling was planned to
achieve good geographical coverage. Each centre was
assigned a number of participants to be recruited, accord-
ing to their activity, over-sampling the smallest, especially
in HRF. In the OTC this was done only for those having
more than 45 annual patients; and in each OTC a con-
venience sample was selected taking into account whether
first treatment and time in treatment. In the HRF, individ-
uals were paid 10€ for their participation. All participants
who agreed to participate signed a consent form. The
study was approved by the IMIM-Hospital del Mar
Medical Research Institute ethical committee. Field-work
was conducted from April to June 2012. Serologic testing
was not used; therefore infection prevalence calculated in
the analysis are based on self-reported data.
Questionnaire
The questionnaire was a piloted, structured ad hoc instru-
ment. The questionnaire was anonymised and included
questions related to socio-demographic characteristics
(age, sex, country of birth, marital status, educational level
and employment status), patterns of drug consumption
(drugs, periods of consumption and whether or not inject-
ing), prison history (ever been convicted of a crime or
imprisoned) and self-reported HIV and HCV serological
status. Information on HCV and HIV serological status
was retrieved from questions asking whether they had ever
had a blood test for HIV/HCV (one at a time) and, if so,
when was the last test and whether a positive result was
ever given. Injecting drug users were defined as individuals
reporting any drug injection at least once in their lifetime.
Statistical analysis
An analysis was made to identify factors associated to
self-reported HIV, HCV and co-infection. Self-reported
co-infected individuals were included in the total num-
ber of infected individuals for self-reported HIV and
self-reported HCV when analysed separately. Only sub-
jects reporting positive serology were considered as such
and were compared to subjects either negative or with
unknown serostatus. The descriptive analysis included
socio-demographic characteristics, pattern of drug con-
sumption and prison history. Comparisons were made
to provide insight into which factors were linked to self-
reported blood borne infections. Correlates were deter-
mined using a Poisson regression with robust variance.
Poisson regression was used instead of logistic regression
because of the high prevalence of infections and because
it allows for direct estimation of self-reported prevalence
ratios (PRs), along with 95 % confidence intervals [CIs].
The chi-square test for categorical variables was used to
compare self-reported BBI differences among IDUs and
drug users who have never injected drugs.
Multivariate models were constructed to identify inde-
pendent correlates of self-reported infection for each
HIV/HCV self-reported infection and co-infection. The
covariates included into the model were: age, sex, coun-
try of birth, current marital status, educational level,
current employment status, injecting drug user, and
prison history. Models included covariates determined to
be statistically important on the basis of associations with
self-reported infection in the univariate analysis (p < 0.20)
and only the statistically significant ones were retained.
The level of significance was set at p value < 0.05. Data
analysis was performed using PASW Statistics for
Windows, version 18.0.
Results
Forty seven centres were included for the sampling of
participants (22 OTC, 13 HRF and 12 TC). A total of
558 individuals with illegal drugs use were approached
for the study: 362 in OTC, 99 in HRF, and 97 in TC.
Forty-two people refused to participate, due to: lack of
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time (45 %), were not interested (19 %) and unknown
reasons (31 %). In addition, four questionnaires were ex-
cluded because they were incomplete (two of them
didn’t report any information related to their serostatus).
A total of 512 individuals were studied, with a median
age of 39 years, 76.56 % were male, 57.81 % had used
heroin and 93.42 % had used cocaine. Overall, 210 sub-
jects (41.02 %) self-reported being positive either for
HIV and/or HCV; the prevalence of HCV was 39.65 %,
for HIV it was 14.84 %, co-infection being reported by
13.48 % subjects. For all proportions, the denominator
includes 83 participants who didn’t know their serosta-
tus (either never been tested or results unknown).
Tables 1, 2 and 3 show the comparisons of socio-
demographic and drug consumption characteristics of
self-reported HIV, HCV and co-infection.
The three self-reported serological status groups
shared similar associations. The median age of self-
reported infected subjects was 41 years for HIV and
42 years for HCV and HIV/HCV co-infection. The
prevalence of self-reported HIV was 18.33 % among
women and 13.78 % among men (p = <0.001). Among
self-reported HCV cases, a higher proportion was found
among men (40.56 %), compared to women (36.67 %),
whereas for self-reported co-infection cases, the propor-
tion was slightly higher for women (14.17 % vs 13.27 %
for men).
The prevalence of HIV, HCV and co-infection in-
creased with early onset of drugs consumption. In the
univariate analysis for the three self-reported serostatus
scenarios, long periods of drug injection were found to
be associated to self-reported infection (participants with
longer periods of injection being more likely to self-
report infection). Self-reported infections among partici-
pants who started drug consumption more recently
(2001–2012), [51(9.96 %)] were much less common, with
only a few cases of HIV [3(3.95 %)], HCV [2(0.99 %)]
and co-infection [1(1.45 %)]. In the multivariate analysis
heroin use was only found to be significant for self-
reported HCV infection. Nevertheless, 10 HCV positive
participants did not report heroin consumption, just
cocaine.
Table 4 describes self-reported serostatus according to
informed parenteral use ever. From the 510 subjects
with known history of parenteral use, 224 (43.92 %) indi-
viduals reported having injected drugs at least once, and
of these, 187 (83.48 %) individuals self-reported to be
positive for HCV and 68 (30.36 %) for HIV, 66 (29.46 %)
individuals were co-infected. Among the drug users who
reported never having injected drugs (N = 286, 56.08 %),
164 (57.34 %) participants self-reported being negative
for both infections the last time they were tested, and
101 (35.44 %) were unaware of their serostatus either for
one infection or both. Twenty-one (7.34 %) participants
self-reported a positive serostatus for HIV and/or HCV
but did not report any parenteral use. Among these 21
individuals, 16 self-reported being positive for HCV, and
eight for HIV, three reported co-infection. Only two
people declared exchanging sex for money. For those that
reported a negative test, the median time since the last
HIV test was 11.41 months (inter-quartile range (IQR) 4-
12) and for the HCV test was 4.5 months (IQR 2–7).
Discussion
In this study of drug users in Catalonia, a high preva-
lence of self-reported HCV (39.65 %) was observed, with
moderate prevalence of self-reported HIV (14.84 %) and
co-infection (13.48 %). As expected these self-reported
infections were strongly associated with parenteral drug
use and length of drug consumption. However, women
were more likely to report being HIV infected or co-
infected, and there was a high proportion of drug users
who have never injected drugs who were unaware of
their serological status. A small proportion (7.34 %) of
drug users reporting never having injected drugs re-
ported being infected.
These results are in line with those of other studies
which suggest that despite the introduction of preventive
interventions (screening, counselling, needle and syringe
exchange programs, methadone programs and other
treatments for substance abuse), transmission persists
and prevalence of blood borne infections, particularly
HCV, continues to be notable in high-risk groups [16],
such as drug users especially IDUs. Currently in Spain,
the route of HIV transmission for 28 % of all Acquired
Immunodeficiency syndrome (AIDS) cases is IDU [17],
and in Europe and the USA, IDU’s account for more
than 60 % of new HCV infections [4, 17].
Our results showed that women who use drugs had a
higher likelihood to self-report HIV infection, than men
who use drugs, but unfortunately, sexual transmission
factors were not collected. Some studies have reported
that women who use drugs more often engage in risky
sexual behaviours, being more likely than men to have
unprotected sex, to have multiple sex partners, to engage
in sex for money or drugs, to use a greater variety of
drugs than men and to be at a higher risk of suffering
violence and marginalization [18–21]. Despite a decrease
in the HIV/AIDS epidemic among IDUs, significant gen-
der differences persist. Women in drug care facilities
constitute a minority, and their gender specific needs
may often be overlooked. Therefore, in the implementa-
tion of HIV prevention strategies, it is crucial to con-
sider a gender perspective when focusing needs of drug
consumers.
Comparing our study with others conducted in Catalonia
[15, 16], prevalence of BBI are similar. However, we have
found a large number of individuals with unknown
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Table 1 Socio-demographic and drug consumption variables associated to self-reported HIV, from drug users in Catalonia, 2012
Total HIV positive HIV negative Bivariate analysisa Multivariate analysisb
n = 512 n = 76 (%) n = 436 (%) PR (95 % CI) PR (95 % CI)
Age, median (IQR) 39 [35–44] 41 [37–45] 36 [32–43] 1 (1.02–1.06) 1.007 (0.98–1.04)
Sex
Men 392 (76.56) 54 (13.78) 338 (86.22) 1 1
Women 120 (23.44) 22 (18.33) 98 (81.67) 1.32 (0.84–2.08) 1.96 (1.27–3.04)
Country of birth
Spain 462 (90.23) 67 (14.50) 395 (85.50) 1
Other countries 48 (9.38) 8 (16.67) 40 (83.33) 1.15 (0.59–2.26)
Unknown 2 (0.39) 1 (50) 1 (50) –
Current marital status
Single 275 (53.71) 46 (16.73) 229 (83.27) 1
Married 120 (23.44) 18 (15) 102 (85) 0.89 (0.54–1.47)
Divorced 89 (17.38) 12 (13.48) 77 (86.52) 0.80 (0.44–1.44)
Unknown 28 (5.47) – 28 (100) –
Educational level
Primary education or less 155 (30.27) 28 (18.06) 127 (81.94) 1
Secondary education 203 (39.65) 27 (13.30) 176 (86.70) 0.73 (0.45–1.19)
Undergraduate education 154 (30.08) 21 (13.64) 133 (86.36) 0.75 (0.45–1.26)
Current employment status
Current regular job 111 (21.68) 2 (1.80) 109 (98.20) 1 1
Unemployment 277 (54.1) 38 (13.72) 239 (86.28) 7.75 (1.9–31.59) 5.00 (1.26–19.91)
Disabled or retired 99 (19.34) 35 (35.35) 64 (64.65) 19.98 (4.93–80.94) 8.92 (2.24–35.60)
Others, including never has worked and worked at home 25 (4.88) 1 (4) 24 (96) 2.26 (0.21–23.96) 1.71 (0.22–12.99)
Number of years by injecting drug consumption
Non-injecting users 286 (55.86) 8 (2.80) 278 (97.20) 1 1
Injection for <6 years 58 (11.33) 10 (17.24) 48 (82.76) 6.19 (2.55–15.00) 4.88 (2.08–11.46)
Injection for 6 to 12 years 27 (5.27) 7 (25.93) 20 (74.07) 9.30 (3.65–23.68) 7.73 (3.08–19.37)
Injection 13 to 22 years 68 (13.28) 29 (42.65) 39 (57.35) 15.30 (7.32–31.96) 12.10 (5.76–25.41)
Injection for >22 years 52 (10.16) 18 (34.62) 34 (65.38) 12.42 (5.70–27.05) 7.73 (3.08–19.37)
Injection for unknown time 21 (4.1) 4 (19.05) 17 (80.95) 6.52 (2.13–19.98) 4.30 (1.19–15.52)
Years after starting drug use, median (IQR) 8.5 [2.4–13.77] 17 [4.80–22.75] 0 [0–4.8] 1.05 (1.03–1.08)
Period of onset of the 1st drug use
2001–2012 51 (9.96) 3 (5.88) 48 (94.12) 1
1991–2000 199 (38.87) 15 (7.54) 184 (92.46) 1.28 (0.38–4.24)
1981–1990 195 (38.09) 44 (22.56) 151 (77.44) 3.82 (1.24–11.79)
1953–1980 64 (12.5) 13 (20.31) 51 (79.69) 3.45 (1.04–11.47)
Unknown period 3 (0.59) 1 (33.33) 2 (66.67) 5.67 (0.81–39.46)
Heroin use
No 216 (42.19) 5 (2.31) 211 (97.69) 1
Yes 296 (57.81) 71 (23.99) 225 (76.01) 10.46 (4.30–25.46)
Prison History
No 393 (76.56) 45 (11.45) 348 (88.55) 1
Yes 119 (23.24) 31 (26.05) 88 (73.95) 3.52 (1.95–6.37)
HIV human immunodeficiency virus, IQR interquartile range, PR prevalence ratio, CI confidence intervals
aUnivariate Poisson regression models with robust variance
bMultivariate Poisson regression model included covariates determined to be statistically important on the basis of associations with infection in the univariate
analysis (p < 0.2)
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Table 2 Socio-demographic and drug consumption variables associated to self-reported HCV, from drug users in Catalonia, 2012
HCV positive HCV negative Bivariate analysisa Multivariate analysisb
n = 203 (%) n = 309 (%) PR (95 % CI) PR (95 % CI)
Age, median (IQR) 42 [37–46] 35 [31–41] 1.05 (1.04–1.06) 1.02 (1.01–1.03)
Sex
Men 159 (40.56) 233 (59.44) 1 1
Women 44 (36.67) 76 (63.33) 0.9 (0.69–1.17) 1.15 (0.99–1.36)
Country of birth
Spain 179 (38.74) 283 (61.26) 1
Other countries 22 (45.83) 26 (54.17) 1.19 (0.86–1.65)
Unknown 2 (100) –
Current marital status
Single 112 (40.73) 163 (59.27) 1
Married 51 (42.50) 69 (57.50) 1.04 (0.8–1.33)
Divorced 33 (37.08) 56 (62.92) 0.9 (0.66–1.22)
Unknown 7 (25) 21 (75) –
Educational level
Primary education or less 71 (45.81) 84 (54.19) 1
Secondary education 80 (39.41) 123 (60.59) 0.86 (0.67–1.09)
Undergraduate education 52 (33.77) 102 (66.23) 0.73 (0.55–0.97)
Current employment status
Current regular job 17 (15.32) 94 (84.68) 1 1
Unemployment 109 (39.35) 168 (60.65) 2.62 (1.65–4.15) 1.52 (1.15–2.56)
Disabled or retired 69 (69.70) 30 (30.30) 4.63 (2.93–7.32) 1.77 (1.30–2.40)
Others, including never has worked and worked at home 8 (32.0) 17 (68.0) 2.13 (1.04–4.37) 1.51 (1.12–2.06)
Number of years by injecting drug consumption
Non–injecting users 16 (5.59) 270 (94.41) 1 1
Injection for <6 years 35 (60.34) 23 (39.66) 10.82 (6.44–18.2) 5.88 (3.27–13.74)
Injection for 6 to 12 years 23 (85.19) 4 (14.81) 15.28 (9.25–25.23) 7.88 (4.46–13.94)
Injection 13 to 22 years 63 (92.65) 5 (7.35) 16.62 (10.28–26.88) 7.77 (4.40–13.74)
Injection for >22 years 52 (100) – 17.94 (11.14–28.88) 7.98 (4.49–14.19)
Injection for unknown time 14 (66.67) 7 (33.33) 11.42 (6.45–20.21) 5.89 (3.14–11.03)
Years after starting drug use, median (IQR) 26 [20–30] 17 [12–23] 1.07 (1.05–1.08) 5.80 (3.09–10.91)
Period of onset of the 1st drug use
2001–2012 2 (3.92) 49 (96.08) 1
1991–2000 46 (23.12) 153 (76.88) 5.87 (1.47–23.36)
1981–1990 111 (56.92) 84 (43.08) 14.44 (3.69–56.49)
1953–1980 43 (67.19) 21 (32.81) 17.13 (4.36–67.37)
Unknown period 1 (33.33) 2 (66.67) 8.5 (1.04–69.35)
Heroin use
No 10 (4.63) 206 (95.37) 1 1
Yes 193 (65.20) 103 (34.80) 14.21 (7.72–26.19) 2.86 (1.42–5.75)
Prison history
No 124 (31.55) 269 (68.45) 1
Yes 79 (66.39) 40 (33.61) 3.35 (2.41–4.65)
HCV Hepatitis C virus, IQR interquartile range, PR prevalence ratio, CI confidence intervals
aUnivariate Poisson regression models with robust variance
bMultivariate Poisson regression model included covariates determined to be statistically important on the basis of associations with reported infection in the
univariate analysis (p < 0.2)
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Bivariate analysisa Multivariate analysisb
n = 69 (%) n = 443 (%) PR (95 % CI) PR (95 % CI)
Age, median (IQR) 42 [37–45] 37 [32–43] 1.05 (1.03–1.07) 1.01 (0.99–1.04)
Sex
Men 52 (13.27) 340 (86.73) 1 1
Women 17 (14.17) 103 (85.83) 1.06 (0.64–1.77) 1.62 (1.01–2.60)
Country of birth
Spain 61 (13.20) 401 (86.80) 1
Other countries 7 (14.58) 41 (85.42) 1.11 (0.54–2.29)
Unknown 1 (50) 1 (50)
Current marital status
Single 42 (15.27) 233 (84.73) 1
Married 18 (15) 102 (85) 0.97 (0.59–1.62)
Divorced 9 (10.11) 80 (89.89) 0.66 (0.33–1.29)
Unknown – 28 (100) –
Educational level
Primary education or less 24 (15.48) 131 (84.52) 1
Secondary education 25 (12.32) 178 (87.68) 0.79 (0.47–1.33)
Undergraduate education 20 (12.99) 134 (87.01) 0.52 (0.83–0.48)
Current employment status
Current regular job 1 (0.90) 110 (99.10) 1 1
Unemployment 34 (12.27) 243 (87.73) 13.87 (1.92–100.11) 8.16 (1.17–56.92)
Disabled or retired 33 (33.33) 66 (66.67) 37.67 (5.25–270.38) 14.10 (1.98–100.48)
Others, including never has worked and
worked at home
1 (4) 24 (96) 4.52 (0.29–69.84) 3.24 (0.28–37.89)
Number of years by injecting drug consumption
Non-injecting users 3 (1.05) 283 (98.95) 1 1
Injection for <6 years 10 (17.24) 48 (82.76) 16.49 (4.68–58.09) 13.04 (3.80–44.78)
Injection for 6 to 12 years 7 (25.93) 20 (74.07) 24.80 (6.80–90.43) 19.50 (5.39–70.55)
Injection 13 to 22 years 28 (41.18) 40 (58.82) 39.39 (12.34–125.78) 29.07 (9.06–93.24)
Injection for >22 years 18 (34.62) 34 (65.38) 33.12 (10.12–108.42) 22.77 (6.90–75.19)
Injection for unknown time 3 (14.29) 18 (85.71) 13.05 (2.80–60.88) 6.98 (1.25–39.06)
Years after starting drug use, median (IQR) 26 [21–30] 20 [14–27] 1.06 (1.04–1.09)
Period of onset of the 1st drug use
2001–2012 1 (1.96) 50 (98.04) 1
1991–2000 12 (6.03) 187 (93.97) 3.06 (0.41–22.99)
1981–1990 42 (21.54) 153 (78.46) 10.93 (1.54–77.51)
1953–1980 13 (20.31) 51 (79.69) 10.36 (1.40–76.58)
Unknown period 1 (33.33) 2 (66.67) 17.00 (1.37–210.31)
Heroin use
No 2 (0.93) 214 (99.07) 1
Yes 67 (22.64) 229 (77.36) 24.67 (6.11–99.60)
Prison history
No 39 (9.92) 354 (90.08) 1
Yes 30 (25.21) 89 (74.79) 3.90 (2.04–7.45)
HCV Hepatitis C virus, HIV human immunodeficiency virus, IQR interquartile range, PR prevalence ratio, CI confidence intervals
aUnivariate Poisson regression models with robust variance
bMultivariate Poisson regression model included covariates determined to be statistically important on the basis of associations with co-infection in the univariate
analysis (p < 0.2)
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serostatus, especially among drug users who have never
injected drugs. In the literature, researchers and policy-
makers have a tendency to focus BBI intervention on IDUs,
ignoring the risk of individuals who use drugs by other
routes. Although one of the most important predictors for
BBI seroconversion is starting injection [22], many risks
have been described among drug users who have never
injected drugs, such as high levels of mixing or “bridging”
with the IDU population [23], and high levels of unpro-
tected sex [24, 25]. Since 2008 the Catalan Surveillance sys-
tem for HIV and HCV (in persons who inject drugs)
recruits from harm reduction centres IDUs having injected
drugs in the previous 6 months. There is no formal behav-
ioural surveillance system for drug users who don’t inject.
Therefore behavioural surveillance should regularly moni-
tor rates of transmission from IDUs to drug users who
have never injected drugs, by including non-injecting users
in the surveillance system, in order to enable the imple-
mentation of timely interventions. In fact, the literature
describes that behavioural surveillance systems should be
integrated in prevention programs that reduce the
likelihood of switching from non-injecting routes to
drug injection [26–28]. Also, it is important to offer
periodic/follow-up and testing access to persons with
ongoing risk factors for exposure to BBIs, and to
offer information to infected persons; particularly to
those who use drugs by injection, about precautions
to avoid exposing others to infected blood.
Strengths and limitations
One of the strengths of this study is the large sample size
and the fact that data were collected from different types
of centres and in towns of different sizes in Catalonia, thus
contributing to the study’s external validity. Results might
reflect changes in the epidemiology of HIV and HCV in
drug users seeking treatment for substance abuse or safe
injecting places in urban areas. However, as the sample
was recruited only from healthcare centres, we cannot ex-
trapolate our results to drug users who do not access these
centres. Nevertheless, our results do not differ greatly
from those of studies with street-recruited participants
(i.e. not selected from therapeutic centres) [13].
Among other limitations of this paper we must men-
tion, first, that it is not possible to make causal infer-
ences due to the study design. However in order to
achieve a more precise assessment of the association in
this type of study design, we used a Poisson regression
model. Second, the rate of BBI positivity may be an
underestimate, first because there was a high proportion
of individuals who reported not having had a serological
test in the last six months and second because it was
based on self-reported serostatus, and thus subject to re-
call and social desirability biases. In order to reduce the
latter, we stressed to participants that their anonymity was
guaranteed. Besides, different studies have shown that the
main results in cross sectional studies are not seriously af-
fected by these forms of bias, and that the results obtained
may be valid despite being self-reported [29]. Third, it is
important to mention that it was not possible to confirm
serological status among positive cases, and that among
negative cases there is still quite a high chance that they
could be infected without knowing it. Even so, prevalence
of infection obtained in this study does not differ greatly
compared to other studies among IDUs [15] .
Conclusions
Among drug users in Catalonia, prevalence of HIV, HCV
and co-infection is still a big issue, especially among IDUs.
However, women and drug users who have never injected
drugs are groups with a significant risk of infection; this
Table 4 Self-reported HCV and/or HIV positive, negative and unknown serostatus by parenteral usea. Catalonia, 2012
Injecting drug users Non-injecting users Total p-valueb
n = 224 (%)c n = 286 (%)d n = 510f (%)e
HCV 187 (83.48) 16 (5.59) 203 (39.80) <0.001
HIV 68 (30.36) 8 (2.80) 76 (14.90) <0.001
HCV + HIV 66 (29.46) 3 (1.05) 69 (13.53) <0.001
Negative self-report of HCV and HIV 26 (11.61) 164 (57.34) 190 (37.25)
Unknown serostatus for HCV 3 (1.34) 24 (8.39) 27 (5.29)
Unknown serostatus for HIV 4 (1.79) 23 (8.04) 27 (5.29)
Unknown serostatus for HCV and HIV 2 (0.89) 54 (18.88) 56 (10.98)
HIV human immunodeficiency virus, HCV Hepatitis C virus
aFirst three rows in the table are not mutually exclusive
bChi square test
cPercentages are the proportion among injecting drug users (IDUs). They do not add up to 100 because co-infected individual count in several categories
dPercentages are the proportion among drug users who have never injected drugs. They do not add up to 100 because co-infected individual count in
several categories
ePercentages are the proportion among the total. They do not add up to 100 because co-infected individual count in several categories
fTwo cases were not included into the analysis due to missing information related with history of drug injection. One reported negative serostatus and the other
one unknown HIV serostatus
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might be related to their engaging in high-risk behaviours
and to ignorance of their serological status. Therefore, it is
crucial to strengthen behavioural surveillance systems in
order to ascertain the serostatus of target populations
such as drug users who have never injected drugs, offering
rapid testing, ensuring access to health care and planning
preventive strategies adapted to the profile of specific sub-
populations with a gender-sensitive approach.
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